Business Wire

P.I.-WORKS

20.4.2021 07:02:11 CEST | Business Wire | Press release

Share
Beeline Russia and P.I. Works Expand Partnership Scope with Automated Radio Access Network Planning

Beeline, Russia’s established mobile operator, has partnered with P.I. Works on network planning project, aimed at streamlining the operator’s investment planning processes and revolutionizing customer experience. As a part of the project, P.I. Works SmartPlan, the cutting-edge automated and AI driven network planning solution, will be deployed nationwide.

Prior to this agreement, P.I. Works provided network planning services for Beeline, which exemplified the SmartPlan’s Return on Investment and Service Quality based planning capabilities. This initial project covered three of Russia’s branches, Moscow, Krasnodar and Novosibirsk, and optimized investments by 19% for high-level technical calculations and resulted in a reduction of 23% of the number of planned sites with LTE extensions. These results highlight the investments that Beeline Russia is making in data networks, and supports the possibility of improving time-to-market, thereby paving the way to a nationwide full-scale automated network investment planning project.

Valeriy Shorzhin, Executive VP, CTO Beeline said, “With customer experience at the forefront of everything we do, network investment planning has never been more fundamental to meeting our strategic objectives. Our aim is to achieve these while maximizing investment cost efficiencies and reducing the planning cycles. After the SmartPlan system is implemented, we intend to undertake in-depth analysis of the data coming from multiple sources in automatic mode. This gives us possibility to calculate high-level site and extension plans with high accuracy in automated mode. We expect this to create a more time-efficient investment planning process, provide more transparent calculations, and enable more structured processes given the intelligent automation capabilities of the system. We are confident that our partnership with P.I. Works will open up new opportunities for both companies.”

P.I. Works’ proprietary Smart Network Planning solution incorporates business and network metrics into a single solution to effectively forecast the network traffic volume and plan future investment decisions. It also uses inputs like Network KPIs, physical site data, point-of-interest locations, crowdsourced data, marketing data and other customer centric data to generate a priority model for investment planning decisions in line with Beeline’s planning policies.

SmartPlan solution orchestrates the investment requirements of different business units in a single platform and incorporates all layers and technologies into one process. This avoids separate planning processes for different business programs and requirements, thus eliminating redundant site investment. The solution also prioritizes the new site investments per region and technology based on Beeline’s planning policies.

Bülent Koca, Sales Director at P.I. Works said, “Teaming up with Beeline has once again proved the success of our commendable track record in network automation. We are proud to be able to cater for the needs of our partner, with the support of our unparalleled network planning offerings. We strongly believe that SmartPlan system will radically transform Beeline’s customer experience levels, all while keeping costs in check.”

About and Disclaimer
https://pi.works/2Qcjnde

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release

News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release

Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye